06:55 AM EDT, 10/11/2024 (MT Newswires) -- Turnstone Biologics ( TSBX ) said Friday it reduced about 60% of its workforce and changed its leadership team as part of a restructuring initiative.

The company said the restructuring would help it focus its resources on the continued development of its phase 1 cancer program, TIDAL-01.

The restructuring initiatives are expected to extend the company's cash runway into Q2 2026.

TIDAL-01 is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, head and neck cancer, and uveal melanoma, with a clinical update expected in H1 2025.

Price: 0.4711, Change: +0.02, Percent Change: +3.79